以青蒿素类化合物为基础的抗疟联合疗法研究进展

Research progress on antimalarial combination therapy based on artemisinin-based compounds

疟疾是一种严重危及生命的传染病,对人类生活产生着深远影响。青蒿素至今仍是世界卫生组织推荐的临床抗疟一线用药,其抗疟活性主要体现在过氧桥结构上。以青蒿素类化合物为基础的联合疗法(ACT)是多国治疗疟疾的一线方法,主要包括蒿甲醚-本芴醇、青蒿琥酯-阿莫地喹和双氢青蒿素-哌喹等。相较于青蒿素单一疗法,ACT具有缩短患者住院时间、加快寄生虫清除速度、节约经济成本等优势,但目前存在耐药性等问题。本文对近年来国内外有关ACT的应用现状及优缺点作一综述,以期为后续筛选ACT中的长效辅助抗疟药物、解决耐药性问题提供思路。

Malaria is a serious and life-threatening infectious disease that has a profound impact on human life. Artemisinin is still the first-line drug for clinical antimalarial treatment recommended by the World Health Organization. The antimalarial activity of artemisinin is mainly reflected in the peroxide bridge structure. Artemisinin-based combination therapy(ACT)is the first-line treatment for malaria in many countries. ACT mainly include artemether-lumefantrine,artesunate-amodiaquine and dihydroartemisininpiperaquine,etc. Compared with artemisinin monotherapy,ACT has the advantages of shortening the length of hospital stay,speeding up parasite clearance,and saving economic costs,etc. However,there are still problems such as drug resistance. This article reviews the application status,advantages and disadvantages of ACT at home and abroad in recent years,in order to provide ideas for the subsequent screening of long-acting adjuvant antimalarial drugs in ACT and to solve the problem of drug resistance.